Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Reslizumab is a type of medicine called a monoclonal antibody that is made in the research
clinic; it works by blocking a specific protein in the body called interleukin-5. The study
medicine, reslizumab, is not yet approved for doctors to treat patients with EGPA. It is
considered an experimental drug in this study.